Peli BioThermal Survey Reveals Biopharma Companies’ Focus on Sustainability in Cold Chain Partnerships

posted on 28th July 2020 by Eddie Saunders
Peli BioThermal Survey Reveals Biopharma Companies’ Focus on Sustainability in Cold Chain Partnerships

Peli BioThermal, the global name in temperature-controlled packaging, today released results of its 2020 Biopharma Cold Chain Logistics Sustainability Survey. According to key opinion leaders in biopharma cold chain, the biopharma industry is increasing its pace to prioritise sustainability in business and operational strategies. Nearly half of all respondents already always factor sustainability into cold chain purchasing decisions.

“Biopharma companies work every day to manufacture and distribute drug products all over the world, and their primary focus is on the safety and efficacy of these life-saving products,” said David Williams, President of Peli BioThermal. “As biopharma companies begin to accelerate work on their sustainability goals, our survey shows they expect the same of their supply chain partners. The cold chain industry needs to continue its focus on improving green thinking to keep pace with its biopharma clients.”

Overall, the survey uncovered three key trends. The first trend indicates that although 66 percent of organisations rate sustainability as very important, valuing sustainability hasn’t yet translated into widespread action. More than half of respondents–53 percent–reported their companies don’t currently use sustainable or green initiatives in their organisations. But organisations have a desire to work with companies that help them advance their sustainability goals, ultimately moving sustainability from valuable to actionable.

In 2015, the United Nations and its member countries created Sustainable Development Goals (SDGs) to guide the world on a sustainable path to 2030. With mounting pressures to improve sustainability, including from consumers and corporate stakeholders, biopharma companies are actively looking for ways to preserve the planet, reduce waste and strengthen their brands.

The second trend speaks to how cold chain partners can help advance biopharma companies’ sustainability goals and how biopharma companies seek to partner with like-minded organisations. More than half (53 percent) of biopharma companies indicate that it’s very important to choose cold chain packaging options that advance their organisation’s sustainability.

Additionally, 64 percent of organisations inquire about sustainability when performing audits of suppliers and 52 percent indicated that they, too, were audited for sustainability by vendors supplying their organisations. It’s not enough anymore to say an organisation is committed to sustainability–proof is now important to prevent legal issues and protect reputation.

The final trend reveals that recyclability and lower emissions matter. Greater focus is being put on how cold chain packaging is constructed, with increasingly high value placed on cold chain packaging that is recyclable or can more easily enter the waste stream. Nearly half of respondents (48 percent) always look for packaging with these characteristics.

Likewise, the industry leans toward lighter, more energy efficient shippers that reduce carbon emissions for temperature-sensitive pharma products being shipped by air. More than half (56 percent) already use these shippers and 81 percent are likely to use energy-efficient packaging in the future. These solutions already exist, allowing biopharma companies to make quick progress toward sustainability goals.

To read the full 2020 Biopharma Cold Chain Logistics Sustainability Survey, visit